
|Articles|December 3, 2007
ARB gets supplemental nod for pediatric hypertension
Valsartan (Diovan, Novartis) approved for use in children
Advertisement
Novartis has received word from the FDA that a supplemental application for angiotensin II receptor blocker (ARB) valsartan (Diovan) has been approved that will permit the drug be used to treat pediatric hypertension in patients six to 16 years old. The tablets were previously approved for use in adults for the treatment of hypertension and heart failure, and to reduce cardiovascular mortality in post-myocardial infarction patients.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Q&A: Pharmacists Can Address ADA Standards Across All Settings
5





























































